ArticleLeukemia2020

RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.

Michael Ruzicka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.